These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4996213)

  • 41. Intravesical adriamycin.
    Pavone-Macaluso M; Pavone C; Cacciatore M; Battista Ingargiola G
    Prog Clin Biol Res; 1985; 185B():123-33. PubMed ID: 3898137
    [No Abstract]   [Full Text] [Related]  

  • 42. [Chemoprophylaxis with intravesical thiotepa in non-infiltrating bladder tumors].
    Lancina Martín J; Monsalve Rodríguez M; Gómez Cisneros S; García Alonso J
    Arch Esp Urol; 1986 Sep; 39(7):479-83. PubMed ID: 3099658
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.
    Zincke H; Utz DC; Taylor WF; Myers RP; Leary FJ
    J Urol; 1983 Mar; 129(3):505-9. PubMed ID: 6403716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravesical chemotherapy and chemoprevention of superficial, low grade, low stage bladder carcinoma.
    Koontz WW
    Semin Oncol; 1979 Jun; 6(2):217-9. PubMed ID: 113878
    [No Abstract]   [Full Text] [Related]  

  • 45. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer.
    Br J Urol; 1994 Jun; 73(6):632-8. PubMed ID: 8032829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.
    Masters JR; McDermott BJ; Harland S; Bibby MC; Loadman PM
    Cancer Chemother Pharmacol; 1996; 38(1):59-64. PubMed ID: 8603453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.
    Burk K; Kurth KH; Newling D
    Prog Clin Biol Res; 1989; 303():423-34. PubMed ID: 2780657
    [No Abstract]   [Full Text] [Related]  

  • 48. [Reoperation for severe hematuria following chemotherapy for bladder papillomatosis previously treated by surgery and cobalt therapy].
    Sauvage R
    Acta Urol Belg; 1981 Jan; 49(1):36-43. PubMed ID: 6782845
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical-experience with thiotepa in the treatment of bladder cancer].
    Gallo FJ; Menéndez-Ondina L; Matallana A; Bonilla JA; Serrano E; Carballido JA; Mendoza A
    Actas Urol Esp; 1978; 2(5):237-40. PubMed ID: 103371
    [No Abstract]   [Full Text] [Related]  

  • 50. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Spontaneously cured pancytopenia due to intravesical thio-tepa, apropos of one case].
    Archimbaud JP; Calcat P; Martel JP
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):487-8. PubMed ID: 4216648
    [No Abstract]   [Full Text] [Related]  

  • 52. Intravesical chemotherapy in the management of superficial bladder tumors.
    Schulman CC
    Prog Clin Biol Res; 1984; 153():275-85. PubMed ID: 6433356
    [No Abstract]   [Full Text] [Related]  

  • 53. [Serious complications following topical administration of thio-tepa in a patient with bladder carcinoma].
    Kaczmarek A
    Wiad Lek; 1978 Apr; 31(8):547-50. PubMed ID: 96607
    [No Abstract]   [Full Text] [Related]  

  • 54. Rationale for intensive intravesical chemotherapy for superficial bladder cancer.
    Soloway MS
    J Urol; 1980 Apr; 123(4):461-6. PubMed ID: 6767860
    [No Abstract]   [Full Text] [Related]  

  • 55. Whither thiotepa (for patients in the USA)?
    Dardis C; Milton K; Ashby L
    J Neurooncol; 2015 Sep; 124(3):529-30. PubMed ID: 26209975
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl.
    Fitzpatrick JM; Khan O; Oliver RT; Riddle PR
    Br J Urol; 1979 Dec; 51(6):545-8. PubMed ID: 534839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [BCG in superficial carcinoma of the bladder. Authors' experience].
    Bordalba Gómez JR; Muñoz Segui J; Aguilo F; Gil Vernet A; Vigues F; Lopez Costea MA; Serrallach N
    Actas Urol Esp; 1992 Jun; 16(6):443-5. PubMed ID: 1509911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Watchful waiting for low-grade Ta bladder tumours: the idea would have been unacceptable 30 years ago, but nowadays we are highly interested in the results of this study exploring it.
    Oosterlinck W
    Eur Urol; 2006 Feb; 49(2):215-6. PubMed ID: 16426733
    [No Abstract]   [Full Text] [Related]  

  • 59. Rationale for intensive intravesical chemotherapy.
    Soloway MS
    Prog Clin Biol Res; 1984; 153():287-95. PubMed ID: 6433357
    [No Abstract]   [Full Text] [Related]  

  • 60. Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
    Russell KJ; Koh WJ; Russell AH; Griffin BR; Markette KL; Tong DY; Griffin TW
    J Urol; 1989 Jan; 141(1):30-2. PubMed ID: 2491760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.